Astellas Pharma Inc Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/5/2026)
| Balance Sheet | Total Assets | 3,567,042,000,000.00 | ROE | 51.33 % |
| Balance Sheet | Total Equity | 1,830,884,000,000.00 | ROA | 8.17 % |
| Cashflow | Capital Expenditures | -57,723,000,000.00 | P/FCF | 8.02 |
| Cashflow | Free Cash Flow | 508,528,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 566,251,000,000.00 | P/CF | 7.20 |
| Income | Earnings per Share (diluted) | 161.78 | Div. Yield | 3.34 % |
| Income | Net Income | 291,535,000,000.00 | P/E | 13.99 |
| Income | Shares Outstanding | 1,802,072,000.00 | P/B | 2.23 |
| Income | Total Revenue | 2,139,245,000,000.00 | P/S | 1.91 |
Ratios calculated on: 10/14/2026
Company Description
Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.astellas.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more